• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 3. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 4. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 5. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126

Recent Advances in the Study of 2-(3,5-Dimethylphenyl)pyrrolidine (CAS: 383127-44-4)

The compound 2-(3,5-Dimethylphenyl)pyrrolidine (CAS: 383127-44-4) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, pharmacological properties, and emerging roles in drug discovery.

Recent studies have highlighted the versatility of 2-(3,5-Dimethylphenyl)pyrrolidine as a scaffold for designing novel bioactive molecules. A 2023 publication in the Journal of Medicinal Chemistry demonstrated its efficacy as a precursor in the synthesis of dopamine receptor modulators, with promising results in preclinical models of Parkinson's disease. The compound's unique structural features, including the pyrrolidine ring and dimethylphenyl moiety, contribute to its ability to cross the blood-brain barrier and interact with central nervous system targets.

Pharmacokinetic studies of 383127-44-4 derivatives have revealed improved metabolic stability compared to earlier generation compounds. Research teams at several academic institutions have reported half-life extensions of up to 300% in rodent models when specific functional groups are introduced at the pyrrolidine nitrogen. These modifications maintain the compound's affinity for target proteins while significantly enhancing its drug-like properties.

In oncology research, 2-(3,5-Dimethylphenyl)pyrrolidine derivatives have shown selective inhibition of histone deacetylases (HDACs), particularly HDAC6. A recent Nature Communications paper detailed how these compounds induce cancer cell apoptosis through dual mechanisms: disrupting protein degradation pathways and modulating epigenetic regulation. The lead compound in this series demonstrated nanomolar potency against multiple cancer cell lines with minimal toxicity to normal cells.

The synthetic accessibility of 383127-44-4 has facilitated structure-activity relationship (SAR) studies across multiple therapeutic areas. A 2024 review in Bioorganic & Medicinal Chemistry Letters cataloged over 50 derivatives, mapping their biological activities to specific structural modifications. This comprehensive analysis has identified key pharmacophores that maintain or enhance activity while reducing off-target effects.

Emerging applications in infectious disease treatment have expanded the potential of this chemical scaffold. Researchers at the Scripps Research Institute recently reported that 2-(3,5-Dimethylphenyl)pyrrolidine derivatives exhibit potent activity against drug-resistant strains of Mycobacterium tuberculosis. The compounds appear to interfere with cell wall biosynthesis through a novel mechanism distinct from existing tuberculosis medications.

Ongoing clinical trials (Phase I/II) are evaluating the safety and efficacy of 383127-44-4-based compounds for neurological disorders. Preliminary data suggest good tolerability and measurable target engagement at therapeutic doses. These developments position 2-(3,5-Dimethylphenyl)pyrrolidine as a promising lead structure for multiple therapeutic applications, warranting continued investigation and development.

• 59347-91-0((2S)-2-phenylpyrrolidine)
• 650607-91-3(Pyrrolidine, 1-butyl-2,5-diphenyl-, (2S,5S)-)
• 650607-87-7(Pyrrolidine, 2,5-diphenyl-1-(phenylmethyl)-, (2S,5S)-)
• 72216-05-8(2-(3-Methylphenyl)pyrrolidine)
• 1270480-16-4(2-(3-Ethylphenyl)pyrrolidine)
• 1006-64-0(2-Phenylpyrrolidine)
• 62506-76-7(2-(4-Methylphenyl)pyrrolidine)
• 56523-47-8((2R)-2-phenylpyrrolidine)
• 295328-85-7((2S,5S)-2,5-Diphenylpyrrolidine)
• 155155-73-0((2R,5R)-2,5-Diphenylpyrrolidine)